Advancing mRNA-based drug development and vaccine manufacturing
Shared by Parexel experts, Christiane Niederlaender, Cecil Nick, and Sinan Sarac covering on the topics of:
Section 1 - Overview of mRNA Product Manufacturing Challenges
Section 2 - Optimizing the Path to Regulatory Approval for Novel Vaccine
Section 3 - Accelerating Approval of mRNA vaccines for Oncology Drug development
Related Insights
Blog
Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications
Feb 4, 2025
Webinar
Accelerating delivery of radiopharmaceutical trials
Oct 3, 2025
Webinar
Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
Nov 12, 2024
Article
Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
Nov 10, 2022
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Blog
PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers
Oct 4, 2024
Blog
Assessing the need for comparative clinical trials in biosimilar development programs
Sep 21, 2023
Whitepaper
Scientific Validity Reports: a mandatory requirement for In Vitro Diagnostic Regulation (IVDR)
Sep 19, 2023
Blog
Studying rare cancer patient populations using integrated genomic and real-world data
Aug 30, 2023
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Whitepaper
Optimizing the Route to Regulatory Approval for a Novel Vaccine
Aug 18, 2023
Related Insights
Blog
Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications
Feb 4, 2025
Webinar
Accelerating delivery of radiopharmaceutical trials
Oct 3, 2025
Webinar
Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
Nov 12, 2024
Article
Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
Nov 10, 2022
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Blog
PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers
Oct 4, 2024
Blog
Assessing the need for comparative clinical trials in biosimilar development programs
Sep 21, 2023
Whitepaper
Scientific Validity Reports: a mandatory requirement for In Vitro Diagnostic Regulation (IVDR)
Sep 19, 2023
Blog
Studying rare cancer patient populations using integrated genomic and real-world data
Aug 30, 2023
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Whitepaper
Optimizing the Route to Regulatory Approval for a Novel Vaccine
Aug 18, 2023